Dulanermin in cancer therapy: Still much to do

Translational Lung Cancer Research

Volumn 1, Issue 2, 2012, Pages 158-159

  Quintavalle, Cristina ^a,b   Condorelli, Gerolama ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879686354     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2012.02.03     Document Type: Editorial

References (15)

1. Falschlehner C, Ganten TM, Koschny R, et al. TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics. Adv Exp Med Biol 2009;647:195-206.
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
3. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12.
4. Schaefer U, Voloshanenko O, Willen D, et al. TRAIL: a multifunctional cytokine. Front Biosci 2007;12:3813-24.
5. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008;27:3845-55.
6. Zanca C, Garofalo M, Quintavalle C, et al. PED is overexpressed and mediates TRAIL resistance in human nonsmall cell lung cancer. J Cell Mol Med 2008;12:2416-26.
7. Incoronato M, Garofalo M, Urso L, et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010;70:3638-46.
8. Garofalo M, Romano G, Quintavalle C, et al. Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Int J Cancer 2007;120:1215-22.
9. Garofalo M, Condorelli GL, Croce CM, et al. MicroRNAs as regulators of death receptors signaling. Cell Death Differ 2010;17:200-8.
10. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
11. Soria JC, Márk Z, Zatloukal P, et al. Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2011;29:4442-51.
12. Soria J-C, Smit E, Khayat D, et al. Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non Small-Cell Lung Cancer. J Clin Oncol 2010;28:1527-33.
13. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer. J Clin Oncol 2010;28:2839-2846.
14. Stern HM, Padilla M, Wagner K, et al. Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab. Clinical Cancer Research 2010;16:1587-96.
15. Pan Y, Xu R, Peach M, et al. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer 2011;105:1830-38.